Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/17/2025

Non-Estrogen Options for Vaginal Lubrication

First-Line Non-Hormonal Options

  • Vaginal moisturizers should be used regularly (3-5 times weekly) for daily comfort and maintenance of vaginal tissue health 1, 2
  • Hyaluronic acid preparations can effectively reduce vaginal mucosal inflammation, dryness, bleeding, and fibrosis 4

Specific Product Recommendations

  • Replens and Sylk are commonly recommended vaginal moisturizers that have shown effectiveness in clinical studies 5

Additional Non-Hormonal Interventions

  • Vaginal dilators may benefit women experiencing vaginismus or vaginal stenosis, particularly those who have undergone pelvic radiation therapy 1, 3
  • Pelvic floor physical therapy can improve sexual pain, arousal, lubrication, and satisfaction 2, 3
  • Lidocaine can be offered for persistent introital pain and dyspareunia 1, 3

When Non-Hormonal Options Are Insufficient

  • If non-hormonal options fail to provide adequate relief, DHEA (prasterone) vaginal cream can be considered, which is FDA-approved for vaginal dryness and pain with sexual activity 2
  • For women without breast cancer history, ospemifene (a selective estrogen receptor modulator) may be considered for moderate to severe dyspareunia 1, 2
  • For women with hormone-positive breast cancer who are symptomatic and not responding to conservative measures, low-dose vaginal estrogen can be considered only after a thorough discussion of risks and benefits 1, 3

Special Considerations for Cancer Patients

  • For breast cancer survivors on aromatase inhibitors, estriol-containing preparations may be preferable if hormonal therapy is absolutely necessary, as estriol is a weaker estrogen that cannot be converted to estradiol 5, 3
  • Vaginal DHEA (prasterone) may be offered to women on aromatase inhibitors who haven't responded to previous non-hormonal treatments 2, 3
  • Be aware that vaginal estradiol may increase circulating estradiol levels in aromatase inhibitor users within 2 weeks, potentially reducing the efficacy of these medications 2, 3